Abcam

Abcam Plc is a global life science company, which distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays, and other kits. The company was founded by David Douglas Cleevely, Anthony Kouzarides, and Jonathan Simon Milner on February 12, 1998 and is headquartered in Cambridge, the United Kingdom.

FREMONT, Calif. and CAMBRIDGE, England, Jan. 4, 2022 /PRNewswire/ -- Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases, and Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life sciences research tools, today announced a strategic partnership to further understanding of the human proteome.

Alamar Biosciences partners with Abcam to drive understanding of the human proteome

Nautilus Biotechnology

SEATTLE and CAMBRIDGE, England, Nov. 2, 2021 /PRNewswire/ -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, and Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences research tools, today announced a strategic development and supply partnership. The relationship leverages Abcam's industry-leading recombinant monoclonal antibody development technologies and expertise to enhance Nautilus' reagent research and development, and establishes a long-term supply relationship between the companies.

Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Proteome

- Completing $340m strategic acquisition of BioVision - Expanding facilities in Eugene, further growing kits and assays portfolio - Supporting the growing demand of the sector and accelerating execution of strategic plan CAMBRIDGE, England, Oct. 27, 2021 /PRNewswire/ -- Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences reagents and tools, today announces the successful completion of its acquisition of BioVision and the expansion of its immunoassay capacity in Eugene, OR. Across the life sciences sector, the events of the last 18 months have amplified the need for efficient workflows and robust data generation, to enable the faster delivery of positive outcomes for science and health.

Abcam completes $340m strategic acquisition and expands kit capacity and capability

51job

Landstar System

SAP SE

According to the Historical Low Price-Book Screen, a Premium feature of GuruFocus, four stocks with high financial strength and are trading near historical low price-book ratios are Landstar System Inc. ( LSTR , Financial), 51job Inc. ( JOBS , Financial), Abcam PLC ( ABCM , Financial) and SAP SE ( SAP , Financial).

4 High Financial Strength Stocks Trading Near Historical Low Price-Book Ratios

CAMBRIDGE, United Kingdom, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, today announces its interim results for the six- and 12-month periods ended 30 June 2021 (the ‘period'). The Group's accounting reference date has changed from 30 June to 31 December1, therefore these interim financial statements report on both a six- and 12-month period.

29% Constant Currency Revenue Growth in H2 as Lab Activity Gradually Recovers and Demand for Abcam In-house Products Increases

Abcam PLC  shares rose on Monday as the research tools maker said it had struck a deal to acquire BioVision Inc, a subsidiary of chemicals firm Chinese firm NKY Medical Holdings, for US$340mln in cash. BioVision distributes research tools and has a strength in the assay kits market, Abcam said, adding that the purchase will bring one of its large third-party suppliers in-house.

Abcam jumps as it snaps up major supplier BioVision

Abcam plc (NASDAQ: ABCM) has agreed to acquire BioVision Inc, a wholly-owned Boai NKY Medical Holdings Ltd subsidiary, for $340 million in cash. The Milpitas, California-based BioVision is a distributor of life science research tools to biopharma, diagnostic and academic customers, with strength in biochemical and cell-based assay kits.

Abcam To Acquire Supplier BioVision For $340M In Cash

CAMBRIDGE, United Kingdom, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM LSE: ABC; Nasdaq: ABCM) ("Abcam", “the Company” or "the Group"), a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire BioVision, Inc. ("BioVision"), a wholly owned subsidiary of Boai NKY Medical Holdings Ltd. (“NKY”), for $340 million (the “Acquisition”).

Abcam to Acquire BioVision for $340 million

Proteomics International Laboratories Ltd (ASX:PIQ) has engaged global life science company Abcam plc (LON:ABC) (OTCMKTS:ABCZF) to manufacture reagents for the immunoassay version of its PromarkerD predictive blood test for the early detection of kidney disease in patients with type 2 diabetes. Abcam is a leader in the supply of life science research tools and reagents, including supply to those companies developing and marketing diagnostic solutions around the world.

Proteomics International engages Abcam to manufacture PromarkerD reagents

CAMBRIDGE, July 13, 2021 /PRNewswire/ -- Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life sciences reagents and tools, today announces the opening of a major new site in Waltham, MA.  The new facility is a central component of Abcam's growth in the United States, reinforcing its commitment to support the research and biopharma sector globally and serving as a hub for the Company's R&D and commercial activities in the region.

Abcam opens new US facility in Boston, MA

I will outline the history of drug development. Information for the Abcam business model will be outlined for my readers.

Abcam: A Promising Business Model In The Drug Industry

SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, England, June 22, 2021 /PRNewswire/ -- Today Pionyr Immunotherapeutics, Inc., a company developing first-in-class antibody therapeutics that increase the body's anti-tumor immunity and Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life science reagents and tools, announced the extension of their collaboration with a new commercial licensing agreement to support the progression of PY314, the first to the clinic of Pionyr's compounds.

Pionyr and Abcam extend partnership to evaluate TREM2-expressing cells in cancer patients

Alexandria Real Estate Equities

They provide the infrastructure and sell the tools that biomedical researchers need to make breakthroughs.

2 of the Safest Biotech Stocks You'll Find Today

CAMBRIDGE, United Kingdom and SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) -- Abcam (AIM: ABC; NASDAQ: ABCM), a global innovator in life science reagents and tools, and MEDx Translational Medicine (MEDx), formerly QIAGEN (Suzhou) Translational Medicine Co., Ltd., a company dedicated to developing companion diagnostics and precision medicine, announced the extension of their strategic partnership to include the co-development and commercialization of key companion and in vitro diagnostic kits for MEDx to supply to the Chinese market.

Abcam and MEDx extend precision medicine strategic partnership

CAMBRIDGE, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a global distribution agreement with ABCAM plc (AIM: ABC; NASDAQ: ABCM) to sell the Group's recently developed SARS-CoV-2 research ELISA Affimer® reagents. Avacta has developed Affimer® reagents which can be used in a high performance ELISA laboratory test to de

Avacta Announces Distribution Agreement With ABCAM plc

Autohome

HealthStream

Stocks with high business profitability and price-book ratios near 10-year lows

5 Companies Trading Below Historical Low Price-Book as of March

CAMBRIDGE, United Kingdom, March 24, 2021 (GLOBE NEWSWIRE) -- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced that Dr Alejandra Solache, SVP of Research & Development received the CiteAb award for ‘Significant Individual Impact' and the Company was recognized as ‘Antibody Supplier Succeeding in Cardiovascular Research'.

Abcam Wins Industry Awards from CiteAb

Abcam (ABCZF) CEO, Alan Hirzel on 2021 Interim Results - Earnings Call Transcript

CAMBRIDGE, United Kingdom, March 08, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (“Abcam”, the “Group” or the “Company”), a global leader in the supply of life science research tools, today announces its interim results for the six month period ended 31 December 2020 (“H1 2021”).

8.3% constant currency revenue growth in H1 as customers gradually return to labs

CAMBRIDGE, United Kingdom, March 04, 2021 (GLOBE NEWSWIRE) -- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced the expansion of its footprint in China with the opening of new custom-built facilities in Hangzhou and Shanghai. Expanded customer service, logistics and manufacturing capabilities are strengthening Abcam's position as a leading collaborator for academia and industry in the region.

Abcam Expands Presence in China to Support Increased Demand of BioPharma Sector

CAMBRIDGE, United Kingdom, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam” or the “Company”), a global leader in the supply of life science research tools, will report its Interim Results for the six-month period ended 31 December 2020 at 12.00 p.m. GMT (7.00 a.m. EST) on Monday, March 8, 2021.

Abcam to Report Interim Results on Monday, March 8, 2021

CAMBRIDGE, United Kingdom, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; LSE: ABC) today announced that Alan Hirzel, Chief Executive Officer, will present at the 2021 SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 8.00 EST / 13.00 GMT. A live webcast of the presentation can be accessed via the IR Calendar page of Abcam's Investor Relations website at https://www.abcamplc.com/reports-presentations.

Abcam to present at the 2021 SVB Leerink Global Healthcare Conference

Abingdon Health signs collaboration and co-marketing agreement with Abcam

CAMBRIDGE, United Kingdom, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam”), a global leader in the supply of life science research tools, is delighted to announce the appointments of Bessie Lee and Mark Capone as non-executive Directors with immediate effect.

Abcam Plc Appointment of Non-Executive Directors

Abcam has a strong position in the niche of supplies for antibody research. It is profitable, dividend paying, and continues to grow well.

News for Abcam Stock (ABCM)